Clinical Data — Partnering & Investment Showcase (January 2006)
16 slides from Clinical Data's conference presentation, Jan 20, 2006
Slide 1: Clinical Data Partnering & Investment Showcase
Clinical Data ® Israel M. Stein MD President, CEO January 19, 2005 Partnering & Investment Showcase
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The following presentation contains certain forward-looking information about Clinical Data that are intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigati
Slide 3: Mission
Pharmacogenomic and molecular tests to guide patient diagnosis and drug efficacy and safety. Providing “Targeted” or “Individualized” therapy. Sequencing, Genotyping, Gene Expression and Metabolomic services to pharma and biotech for all stages of drug development and post-surveillance monitoring. T
Slide 4: Corporate Structure
Clinical Data, Inc. Newton, MA NASDAQ National Market CLDA Market Cap: $120 MILLION Revenues: $100 MILLION ANNUALIZED Shares Outstanding: 6.7 MILLION 475 employees worldwide Corporate Structure
Slide 5: 2005 Growth Story
Boston Globe 100, May 2005 #9 overall #1 in growth Business Week, May 2005 #29 of 100 “Hot Growth Companies” Business 2.0, June 2005 #3 Fastest Growing Tech. Companies Fortune September 2005 #10 Overall 2005 Growth Story
Slide 6: Genomic Services
- Pharmacogenomics Molecular diagnostic services Regulated and Research Houston, Texas New Haven Connecticut Morrisville, North Carolina Cambridge, England - Raleigh, North Carolina Molecular Diagnostic Services Gene Expression Metabolomics Genomic Services Genaissance Pharmaceuticals, Inc. Icoria,
Slide 7: Classical Diagnostics
- Smithfield RI and Brea CA Laboratory equipment distribution, reagent manufacturing - Spankeren, The Netherlands Instrumentation Development and Production - Sydney AU Diagnostics distribution and immunoassay reagent production Forli, Italy ESR Immunochemistry Instrumentation Classical Diagnostics
Slide 8: Quality and Regulatory
U.S. genomics operations GLP & CLIA certified ISO 9001 and 13485 certified. FDA certified US & European manufacturing facilities. European IVD standards Australia GMP licensed Quality and Regulatory
Slide 9: Genaissance Pharmaceuticals
Improve safety & efficacy of medications by “individualizing” therapy based on genetic makeup. Improve drug development and r escue “stalled” drugs by demonstrating the role of genetic variation in drug response. Develop clinical diagnostic assays Offer CLIA approved clinical molecular diagnostics (
Slide 10: Icoria
Develop biomarkers based on gene expression and metabolomics (biochemical pathways) . Finding new ways of detecting early stage evidence of liver injury and diabetes. Provide molecular services to pharma, biotech, government and academia. Icoria Acquired December 2005
Slide 11: Genomics Services
Sequencing Genotyping Molecular Sciences Gene Expression/Pathway Analysis Extraction and BioBanking Product Lifecycle Supports development of Biomarkers and Clinical PGx Products Genomics Services Research Phase Clinical Dev. Preclinical Dev. Post Launch
Slide 12: Classical Diagnostic Products
Chemistry and Hematology analyzers Manufactured and distributed worldwide. Clinical Chemistry/Coagulation - Netherlands ESR- Italy Cell Counters - OEM from France. Clinical Chemistry Assays and Supplies Reagents produced in USA. Worldwide distribution. OEM assays - Daiichi-Sankyo - Japan Classical D
Slide 13: Selectra-E
Selectra-E 5500 instruments worldwide Three Analyzers – One Chemistry 180 test per hour 360 tests per hr + 100 ISE Marketing Partner Dade Behring
Slide 14: Seeking Opportunities
To expand and optimize worldwide operations To leverage existing analytical platforms in PGx Identify new and complimentary clinical assays In-licensing of IP M&A and partnering opportunities Seeking Opportunities
Slide 15: Seeking Opportunities: Become a Market Leader in Clinical PGx Testing
Identify new IP in CNS, Cardiac Disease and Oncology Utilize CLIA approved laboratory status in U.S. to formulate and commercialize “Home Brew” diagnostic assays. Rescue “stalled” drugs through PGx Seeking Opportunities BECOME A MARKET LEADER IN CLINICAL PGx TESTING
Slide 16: Clinical Data
Clinical Data ®
Clinical Data — Partnering & Investment Showcase (January 2006) on 6ix